#United States #Denver #Neurotek #MOXO360 #Attention Assessment

Neurotek Introduces MOXO360™

Neurotek, recognized as a leader in digital cognitive assessments, has recently launched MOXO360™. This innovative assessment tool is set to become essential for mental health professionals, providing an unprecedented approach to understanding cognitive functions and attention. MOXO360™ was unveiled just before the American Psychological Association (APA) 2025 Annual Meeting in Denver, which suggests the significance and timeliness of this release in the mental health sector.

A Comprehensive Approach to Cognitive Assessment

MOXO360™ stands out in the marketplace for its holistic approach to cognitive evaluation. While traditional assessments have largely relied on symptom-based diagnostics, MOXO360™ integrates clinical diagnostics with cognitive profiling. This enables professionals to gain deeper insights into the attentional strengths and weaknesses of individuals, moving beyond mere symptom observation. The blend of clinical and cognitive data allows for better targeting of interventions, crucial for effective treatment plans.

Features That Elevate Mental Health Assessment

MOXO360™ offers several notable features that redefine cognitive evaluation:

• - Integrated Assessment: The tool combines clinically validated diagnostics with a pioneering cognitive attention profiler, delivering a streamlined solution for users.

• - Comprehensive Reporting: Users can access three detailed reports:

- MOXO Diagnosis Report: Utilizes clinically aligned results benchmarked against a norms-based sample.
- MOXO Profiler Report: Provides a cognitive attention profile, compared to a dataset derived from nearly 58,000 tests globally.
- MOXO360™ Report: Summarizes clinical and cognitive insights for effective intervention planning and progress tracking.

• - Advanced Data Visualizations: Interactive profile views and performance change graphs assist professionals in swiftly identifying trends and monitoring improvements.

• - Real-World Relevance: The tool includes standardized distraction scores (across audio, visual, and combined scenarios) which enhance the understanding of cognitive function in everyday situations.

Tailored for Diverse Professionals

MOXO360™ is developed with a variety of users in mind:

• - Clinicians: Supporting diagnoses of ADHD and formulating ongoing treatment plans.
• - Educators: Assisting in the creation of evidence-based strategies for students with attentional challenges.
• - Researchers: Aiding in the tracking of cognitive outcomes across varied population samples.
• - Organizations: Furnishing objective cognitive data for recruitment, training, and overall performance enhancement.

Seamless Transition for Existing Users

Current users of the MOXO Diagnosis assessment can transition to MOXO360™ effortlessly, preserving access to their historical results while unlocking new insights. Tests completed in the last two years can be retrospectively upgraded, facilitating extensive longitudinal analysis without data loss.

Setting a New Standard in Cognitive Evaluations

Dr. Jacob (Yaki) Dayan, CEO of Neurotek, remarked, "As mental health care transitions toward data-driven, customized methodologies, MOXO360™ establishes a new industry benchmark in clarity and actionable insight. This comprehensive view facilitates informed decision-making, crucial for real-world outcomes."

The comprehensive functionalities of MOXO360™ are set to transform cognitive assessments for mental health professionals, enhancing the understanding and treatment of various cognitive challenges.

MOXO360™ is currently available for demos and pre-orders during the APA 2025 event in Denver, marking a significant step forward in cognitive assessment solutions. Interested parties wishing to engage with the Neurotek team during the event can contact them to schedule a meeting.

About Neurotek

Founded in 2014, Neurotek has positioned itself as a forerunner in digital cognitive assessments. The flagship MOXO ADHD digital tool is employed across more than 50 countries, supporting healthcare systems, academic institutions, and clinics in their efforts to apply data-backed decision-making processes. Supported by over 100 peer-reviewed publications, Neurotek continues to lead the way in the evolution of cognitive assessment methodologies, with MOXO360™ set to redefine the field for years to come.